Related Experiment Videos
[Long term treatment with acebutolol in hypertension (author's transl)]
Insights
Acebutolol effectively lowers blood pressure in hypertensive patients, with significant reductions observed early in treatment. This cardioselective beta-blocker demonstrates good tolerability and efficacy for hypertension management.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypertension remains a significant global health concern requiring effective therapeutic agents.
- Cardioselective beta-adrenoceptor antagonists offer targeted treatment options for managing elevated blood pressure.
Purpose of the Study:
- To evaluate the efficacy and tolerability of acebutolol in hypertensive patients.
- To determine optimal dosages and assess side effects of acebutolol treatment.
Main Methods:
- A 6-month study involving 40 hypertensive patients, divided into two groups based on prior antihypertensive use.
- Patients received acebutolol, with dosage titration over three months.
- Blood pressure and heart rate were monitored regularly, along with assessment of side effects.
Main Results:
- Significant blood pressure reduction was observed by the 15th day of acebutolol therapy in both patient groups.
- Diastolic blood pressure decreased below 90 mmHg in 41% of patients after 3 months.
- Average heart rate was significantly reduced, with minimal side effects reported, including two cases requiring treatment discontinuation.
Conclusions:
- Acebutolol demonstrates good efficacy in treating hypertension.
- The drug exhibits a high degree of tolerability, making it a viable option for long-term hypertension management.
Abstract:
Acebutolol, a new cardioselective beta-adrenoceptor antagonist, has been studied in 40 hypertensive patients (pts.) for a period of 6 months, 25 patients (group A) had never taken any antihypertensive agent, 15 pts. (group B) were previously treated with antihypertensives. This two groups are statistically different for the age (39.8 y. group A; 49.6 y. group B) for the values of basal blood pressure (BP) (175/105 mmHg group A; 197/114 mmHg group B) and for disease duration (9.9 months group A; 39.0 months group B). A significant antihypertensive response was obtained already at the 15th therapy day for the two groups, treated with acebutolol. Further, a little reduction of BP was obtained at the 3rd month going on with therapy; then the BP values showed non significant variation till the end of the study. Orthostatic hypotension were not remarked. After 3 months, acebutolol treatment 41% pts. rised diastolic BP (DBP) below 90 mmHg and 35% pts. had a DBP between 90 and 100 mmHg. The average values of heart rate have been significantly reduced after 15 days of therapy with sligh variations during the following month. The optimal mean daily dosages of the drug were obtained with titration in three months (540 mg/day group A and 740 mg/day group B). Regarding side effects rised during therapy, one patient showed "paradox hypertension" and another bradycardia which justified the interruption of the treatment. In our opinion, on the basis of the results obtained acebutolol shows a good efficacy in the treatment of hypertension and a very high tollerability.